With rapid advances in nanomedicine, magnetic nanoparticles (MNPs) have emerged as a promising theranostic tool in biomedical applications, including diagnostic imaging, drug delivery and novel therapeutics. Significant preclinical and clinical research has explored their functionalization, targeted delivery, controllable drug release and image-guided capabilities. To further develop MNPs for theranostic applications and clinical translation in the future, we attempt to provide an overview of the recent advances in the development and application of MNPs for drug delivery, specifi cally focusing on the topics concerning the importance of biomarker targeting for personalized therapy and the unique magnetic and contrast-enhancing properties of theranostic MNPs that enable image-guided delivery. The common strategies and considerations to produce theranostic MNPs and incorporate payload drugs into MNP carriers are described. The notable examples are presented to demonstrate the advantages of MNPs in specifi c targeting and delivering under image guidance. Furthermore, current understanding of delivery mechanisms and challenges to achieve effi cient therapeutic effi cacy or diagnostic capability using MNP-based nanomedicine are discussed.
Introduction
Actual therapeutic effect on diseased tissues, with negligible systemic toxicity toward normal organs or tissues, is dependent on the effective delivery of therapeutics to the diseased sites, which cannot be realized by most of the conventional therapeutics alone. Generally, intravenously (i.v.) administered drugs with low molecular weights are cleared out of the body rapidly
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Currently, more than 80 newly developed therapeutic nanoformulations are under investigation in preclinical studies and clinical trials. In spite of the great potential demonstrated by nanomedicine, future development and translation of effi cient delivery of nanotherapeutics are needed to overcome several major challenges in order to make a real impact on clinical care of patients. In particular, there is a need in new strategies for improving effi ciency with localized precision delivery and quantitative assessment of drug delivery and treatment response.
Magnetic nanoparticles (MNPs) composited with metallic, alloyed metallic, ferrites (MFe 2 O 4 , M = Fe, Co, Ni, Mn) and magnetic elements doped ferrites have been widely investigated as drug delivery systems. The advantages of MNPs, as illustrated in Figure 1 , are built upon their availability and unique physical/chemical properties, such as simple and robust preparation methods, good biocompatibility, reactive functional groups on the surface, and magnetic responsiveness. The most widely studied and applied MNPs are iron oxide nanoparticles (IONPs), or superparamagnetic iron oxide nanoparticles (SPIOs) as referred in some other literatures, due to their well-known excellent biocompatibility compared with other heavy metal containing nanomaterials (e.g., quantum dots, gold nanoparticles, or carbon nanotubes (CNTs)) that are hard to be degraded and eliminated from the body. [ 5 ] Five IONPs (Gastromark, Feridex, Resovist, Sinerem, and Ferumoxytol) have been approved by the U.S. FDA and/ or the European Commission (EC) as magnetic resonance imaging (MRI) contrast agents (Gastromark, Feridex, Resovist, and Sinerem) or iron supplement for treating iron deficiency (Ferumoxytol). These approved IONPs are made mostly through co-precipitation method without any functionalization, and found accumulating mainly in the liver and spleen (50-80%), in which IONPs are then ingested and converted into the form suitable for iron storage. [ 7, 8 ] Clinical doses of IONPs in humans are determined between 0.56-3 mg Fe/ kg patient body weight, which is much less than the normal blood iron concentration (≈33 mg Fe/kg body weight) and relatively low compared with total body iron (≈3,500 mg). Although the potential toxicity is determined by particle component, size, shape, surface charge, coating materials, etc., a variety of MNPs have shown no signifi cant or minimal negative effect on the liver or kidney function after i.v. administration. [ 7, 8 ] Following functionalization with targeting ligands and drugs, increased amount of MNPs may accumulate at the targeted site via passive or active targeting to improve the therapeutic effi cacy and even allowing a more aggressive/ higher drug dosage. In addition, unique magnetic properties of MNPs enable MRI for evaluation of drug delivery effi ciency, image guidance during delivery process, non-invasive monitoring of treatment responses, and external magnetic stimulated manipulations, such as magnetic fi eld guided localization and hyperthermia, to enhance delivery and/or combined therapeutic effect. Hence, MNPs are excellent candidates for targeted drug delivery and image-guided therapeutics that have the potential for novel clinical applications in individualized medicine.
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Magnetic Nanoparticles as Drug Carriers
The design and preparation of functionalized MNPs for drug delivery require interdisciplinary approaches, taking into consideration of the physico-chemical properties of materials (i.e., payload drugs and drug carriers), their behaviors and responses in the biological or physiological environment, and the intended functions that address relevant medical problems. In order to have effi cient drug delivery, MNP-based drug carriers should be able to: (i) possess the capacity of loading suffi cient drug molecules, (ii) protect drug bioactivity and enhance biocompatibility, (iii) target to the intended delivery sites with less uptake by the normal organs and/or tissue. Depending on the needs of a given size uniformity and crystallinity of MNPs or simplicity of the preparation methods, a number of preparation methods have been developed and adopted to produce the core of MNPs with uniform size, controlled shape, and desirable compositions, including co-precipitation, [ 7 ] thermal decomposition, [ 8 ] hydrothermal deposition, [ 9 ] direct reduction, [ 10 ] microemulsion, [ 11 ] and polyol synthesis [ 12 ] , etc. Using MNPs as core materials, various functional organic (e.g., polymer, [ 13 ] lipid, [ 14 ] and protein [ 15 ] ) or inorganic (e.g., gold, [ 16 ] silica, [17] [18] [19] graphene oxide, [ 20 ] and CNTs [ 21 ] ) materials can be assembled with MNPs to provide the capacity of incorporating payload drugs to improve drug solubility for the systemic delivery.
Surface modifi cation is usually required to make MNPs compatible with the properties of therapeutic agents, so that the drugs can be properly loaded and effectively released after delivering to the diseased sites. The most commonly used drug loading methods include direct encapsulation or adsorption of the drugs through physical interactions (e.g., hydrophobic interaction or electrostatic attraction) between the MNPs and the drug molecules or chemical reactions (e.g., covalent bonding through active groups) between the surface functional groups of MNPs and drug molecules, as shown in Figure 2 . Drug loading effi ciency can be highly dependent on the structures and polarities of drugs, the compositions and capacity of coating materials used in MNPs, and the numbers of functional groups on MNP surfaces. Therefore, engineering MNPs with appropriate coating materials and controlled surface properties is a common strategy to improve the drug loading. It has been shown that more hydrophobic drugs can be encapsulated into the coating layer of MNPs (e.g., 15 wt% of DOX loading) by increasing the thickness or porousness of the hydrophobic layer of the amphiphilic polymer coating. [ 22 ] In some cases, additional coating layers (e.g., polyethylene glycol (PEG) and protein) are applied to further protect payload drugs from premature release, and to conjugate targeting moieties via covalent bonding through specifi c crosslinkers (e.g., EDC/NHS, SPDP, and SMCC) or click chemistry (i.e., azide group) as illustrated in Figure 2 . Table 1 summarizes some therapeutic agents that have been investigated as payload drugs for MNP-based delivery and several related methods used for drug loading and releasing.
Drug Loading through Hydrophobic Interactions
Hydrophobic therapeutic agents (e.g., doxorubicin, camptothecin, paclitaxel, etc.) that consist of more than 40% of currently used chemotherapy agents, are poorly soluble in the aqueous physiological conditions, resulting in very limited delivery effi cacy. [ 23 ] However, those hydrophobic drugs can be easily incorporated into the hydrophobic layer of amphiphilic polymers that are commonly used to stabilize MNPs, driven by their hydrophobic interaction between each other and the repulsion from aqueous surroundings as illustrated in Figure 3 A. [ 22, 24, 25 ] In a typical process, a hydrophobic drug is fi rst dissolved into an organic solvent with appropriate polarity (e.g., DMSO, DMF, and methanol), followed by soaking the engineered MNPs in drug solution, in which the polymer coating may swell, allowing the drug diffuse to the hydrophobic coating layer/cavities. Subsequent products are collected and re-dispersed into the aqueous solution, resulting in the collapse of the inner hydrophobic layers beneath the hydrophilic outer layers. Hydrophobic drugs can be well preserved in the hydrophobic layers during the delivery process, and then released slowly after long time exposure to the physiological conditions or relatively fast under specifi c conditions. Such a sustained release profi le is essential to maintaining a sufficient level of nanoparticle-drug carriers in the circulation, in Figure 1 . Properties of MNPs for the development of drug delivery systems, including simple and robust preparation methods, good biocompatibility, facile functionalization through reactive functional groups on surface, and responsiveness to exogenous energy or specifi c physiological conditions.
wileyonlinelibrary.com © 2016 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim order to deliver into the diseased tissues subsequently, which cannot be achieved by small molecule drugs that are cleared rapidly. Once accumulated in the targeted site, encapsulated hydrophobic drugs can be released through different mechanisms. Change of the polarity of drug molecules or tissue/ cellular environment may lead to the release of encapsulated drug molecules. For example, with pH-responsive polymer coatings (e.g., mPEG-b -poly(methacrylic acid)-b -poly(glycerol monomethacryate) and mPEG-poly(L-asparagine)), drugs can be released after MNPs arrived at lower-pH sites, such as tumor interstitial (pH 6.5-6.8) or cellular endosome/lysosome (pH 4.5-5.5), stemming from the protonation of the coating polymers that change structure or hydrophilicity, [ 26 ] or the dissociation of coating layer from the MNP core. [ 27 ] Since MNPs are able to induce a hyperthermia effect under an alternating magnetic fi eld (AMF), thermo-responsive triggering is another mechanism to release the drugs that loaded in MNP carriers through hydrophobic interaction. During the exposure to AMF, MNPs may generate heat that increases temperature to a few degrees higher than the phase transition temperature ( T g) of the thermosensitive polymers, leading to the softening and swelling of the polymer phase, and subsequent release of loaded drugs. For example, Hayashi et al. used thermosensitive amphiphilic polymer (polymerized pyrrole-3-carboxylic acid (PyCOOH)) coated MNPs to load Dox, and observed more than 60% of the Dox content was released at T g (≈44 °C), and about 90% at 46 °C when exposed to an AMF (230 kHz, 8 kA m -1 . [ 28 ] The remote, on-demand release of anticancer drugs assisted by AMF largely enhances the specifi city of drug delivery as the temperature and direction can be easily regulated by using AMF.
Drug Loading through Covalent Bonds
Conjugating or cross-linking therapeutic agents to the functional groups on the functionalized MNP surface is another approach to carry payload drugs. The covalent bonding of drug molecules to the surface of MNPs is stable enough to secure drug molecules remaining on the MNP carriers during in vivo delivery. However, the release of payload drugs is relatively diffi cult. Therefore, a cleavable linkage between drugs and MNPs is usually used to enable the selective and controlled release of the drug molecules. The most commonly used cleavable linkers include amide and hydrazone bonds, which can be cleaved under lysosomal pH (pH = 5.0) to release the loaded drugs (e.g., Dox, methotrexate, paclitaxel, etc.) [ 29, 30 ] Besides the pH-responsive bonds, given a specifi c enzyme-cleavable linker, the release of payload drugs can be highly controlled. For example, Lee et al. developed theranostic MNPs with chemotherapy agent gemcitabine (Gem) conjugated on the surface of IONPs via a cleavable tetrapeptide linker that can be cleaved by the enzyme cathepsin B, a protease located in the lysosome of cells (Figure 3 B) . [ 31 ] After the receptor-mediated endocytosis of the ATF-IONP-Gem into pancreatic tumor cells, Gem was then released intracellularly in the lysosomes upon the cleavage of the peptide linker by cathepsin B. The intracellular release is critical as Gem is much more potent and effi cient in killing pancreatic cancer cells given its action of blocking DNA replication.
In addition, thermal induced linker cleavage has also been explored when using MNPs as drug carriers. For example, after conjugating with the surface coating that composed of a dextran-based polymer through hydrazone bond, Dox can be released from MNP carriers by a phase transition at the lower critical solution temperature of 38 °C. [ 32 ] N'Guyen et al. showed that magnetically induced hyperthermia could provide sufficient local energy to trigger the retro-Diels-Alder process, thus breaking a linkage formed by a "click" reaction. [ 33 ] Notably, "click" reactions and other bioorthogonal reactions are widely used for the targeting ligand conjugation but rarely for drug loading due to the stability of the formed chemical bonds. [ 34 ] Several issues have to be considered when using covalent bonding to load/carry drugs. First, the limited number of active functional groups on the surface of MNPs may restrict the drug loading amount. Secondly, this approach requires proper criteria or design of the linker and reactions with strictly controlled reaction conditions. Furthermore, the bioactivity of the loaded drugs, as well as the MNP stability, may be affected during the chemical reactions.
Drug Loading through Electrostatic Interactions
Electrostatic interactions are typically used for loading of nucleic acid and nucleotide drugs for gene therapy. For DNA or small interfering RNA (siRNA), cationic coating polymers, such as PEI, [ 36, 37 ] polyamidoamine, [ 38 ] or chitosan [ 39 ] wileyonlinelibrary.comemployed as coating materials to interact with the negatively charged nucleic acids. These coating materials not only protect the nucleic acids from enzymatic degradation, but also facilitate the endosomal release of nucleic acids through "proton sponge effect", [ 40 ] in which massive accumulation of protons is induced in endosomes leading to its osmotic swelling and consequently the burst release of nucleic acids into the cytoplasm. [ 41 ] In general, in vivo applications of these systems are limited due to the toxicity and stability concerns. [ 2 ] However, a recent study has demonstrated that PEI-PEG-Chitosan copolymer coated MNPs and MNP-polymer composite interlayer with a relatively neutral lipid shell can be utilized as a safe carrier for gene delivery both in vitro and in vivo (Figure 3 C). [ 35, 42 ] 
Drug Loading through Direct Encapsulation
Liposomes and micelles that are composed of amphiphilic molecules can be used for direct encapsulation of MNPs and therapeutic agents. Both of them exhibit remarkable capability in accommodating both hydrophilic [ 43 ] and hydrophobic MNPs. [ 44 ] For example, using an amphiphilic biodegradable poly(lactic-co -glycolic acid) polymer, MNPs and quantum dots can be encapsulated together with the anticancer drug busulfan, [ 45 ] where a 32% of degradation of the micelle into lactic and glycolic acid over fi ve weeks was observed in the in vitro study. By combining gold nanoparticle as radiosensitizer and MNPs as MRI contrast agents into micelles as shown in Figure  3 D, image-guided radiotherapy was demonstrated to be effective in a human fi brosarcoma xenograft tumor mouse model ( Figure 3 D) . [ 46 ] Another example is Amstad et al. embedded small MNPs that are stabilized with palmityl-nitroDOPA into the lipid membranes but not the cavities to better control the drug release. [ 47 ] Upon the stimulation of AMF, MNPs in the liposome bilayers generated heat to increase local temperature to the membrane melting temperature ( T m , 55 °C), which is much higher than the bulk temperature, to release the drug without disrupting the liposome structure. Besides liposomes and micelles, other materials (e.g., zeolite and mesoporous silica) have also been employed for drug encapsulation. MNPs and small molecules, including fl uorescein and an anticancer drug camptothecin, could be encapsulated in the zeolitic imidazolate framework-8 (ZIF-8), forming a drug loaded nanocomposite of 70 nm sized that can dissociate in the endosome to release the cargo. [ 48 ] 3. Targeted Delivery of Theranostic MNPs
EPR Driven Passive Targeting
The delivery of theranostic nanoparticles, such as MNPs, to the diseased tissues, particular in cancer treatment, is initially driven by the enhanced permeability and retention (EPR) effect. The EPR effect, fi rst reported by Maeda and his colleagues in 1986, [ 49, 50 ] describes the enhanced permeability of the tumor vasculature that allows macromolecules, lipids, and nanoparticles circulating in the blood to extravasate through the leaky tumor blood vessel, then enter the tumor interstitial space. [ 51 ] Meanwhile, dysfunctional or lack of lymphatic drainage in tumor further retains the MNPs within the tumor by preventing nanoparticles getting back to the circulation. [ 50, 52 ] As a result systemically administered nanoparticles can preferentially accumulate in tumor tissues, leading to passive targeting of a tumor without targeting ligands. In contrast to normal tissues and organs, most solid tumors feature rapidly developed tumor vasculature with loose tight-junction and fenestration of endothelial cells, and abnormal or missing basement membrane of blood vessels, which collectively cause increased tumor vasculature permeability. [ 49, 53, 54 ] Fenestrations presented in the tumor blood vessel walls have a size range of 200 to 2000 nm, [ 54, 55 ] allowing MNPs to pass through the leaky vessel walls.
To take advantage of the EPR effect mediated passive targeting of the tumor, the size of drug-MNP assembly needs to be smaller than the fenestrations in tumor vessel walls (200-2000 nm) for extravasations. Once extravasated, the penetration of the drug carrying MNPs into the tumor tissues is a diffusion-mediated process, which is inversely correlated with the particle size. Thus, considerable research has been focused on fi nding the optimized particle size for EPR-mediated delivery. [56] [57] [58] In general, MNPs with sizes in the range of 10-500 nm are believed to be suited for EPR effect-mediated tumor accumulation. [ 56 ] On the other hand, surface charge of theranostic MNPs also plays an important role in EPRmediated passive tumor targeting. It has been shown that the luminal surface of vascular endothelial layer is negatively charged, therefore, nanoparticles with the cationic charge can rapidly interact with endothelial cells, causing non-specifi c binding that shortens the plasma half-life, and a consequently reduced the EPR effect. [ 59 ] Nanoparticles with highly negative charges are prone to be trapped by organs in the reticuloendothelial system (RES) such as liver and spleen. However, MNPs with neutral surface charge are diffi cult to be sterically stabilized. Taking together, a slightly negative surface charge of MNPs is considered to be better for a longer blood circulation time, though the surface charge is not a dominant factor for blood clearance, which is more dependent on MNP size and component. [ 60 ] Besides the size and surface charge, the shape of MNPs is another critical factor regulating the MNP drug delivery. It has been known that nanomaterials with elongated structures and shape demonstrate favorable pharmacokinetic and tumor-homing properties compared to their spherical counterparts. [ 61 ] This is because nanomaterials with high aspect ratios have a larger surface area than spherical particles, offering more potential binding sites for functionalization, and consequently greater loading with targeting ligands, imaging agents and/or drugs. Steinmetz et al. reported that the rod-like, high aspect ratio, viral nanovector showed enhanced tumor homing and tissue penetration properties than the spherical viral nanovectors. [ 61 ] 
Ligand Facilitated Active Targeting
While passive targeting through the EPR effect provides the general mechanism for delivering a broad range of nanoparticle carriers, targeting ligand facilitated active targeting of molecular or cellular biomarkers further enhances the precision and targeted delivery of the therapeutic agents that are biomarker specifi c and require direct interactions of the drug molecules and biomarkers. Furthermore, active targeting with binding of the ligand conjugated MNPs to over expressed cell surface receptors promotes the intracellular delivery of therapeutic agents through receptor mediated endocytosis, as shown in Figure 4 . For example, transferrin (Tf, 80 kDa) is an iron-chelating protein that targets transferrin receptor (TfR, 180 kDa, also known as CD71), a transmembrane glycoprotein. [ 62, 63 ] Generally the overexpression of TfR can be observed on the surfaces of proliferating cancer cells due to an increased iron requirements but its level in many normal tissues is low. TfR-mediated Tf internalization is a very fast process (less than 5 min), leading to the turnover rate of 20,000 Tf/cell/min. [ 64 ] This allows greater accumulation of Tf conjugated MNPs at the target site, resulting in a stronger contrast and higher local drug concentration. [ 65 ] In addition, the consistent TfR expression level through all tumor development stages makes TfR a more reliable biomarker for tumor targeting and drug delivery. [ 64 ] Typically targeting ligands can be categorized into proteins, peptides, aptamers, and small molecules. Antibodies and other functional proteins are natural choices of targeting ligands because of their high specifi city and affi nity toward the disease biomarkers. Furthermore, some antibodies carry the therapeutic effect by themselves. For example, Herceptin (commercially marketed as Trastuzumab) is monoclonal antibody used to treat early stage (curable) breast cancer with high expression of HER2/neu receptor which is a human epidermal growth factor receptor essential for cell proliferation. Trastuzumab treatment improved overall survival and disease-free survival of HER2-positive breast cancer patients. Herceptin can be also used as the ligand for targeting HER2-positive breast cancer. [ 67 ] Hence, Herceptin conjugated MNPs have been developed for HER2-positive breast cancer imaging and treatment. [67] [68] [69] Given the concerns of immunogenic side effect, stability and the high cost usually associated with antibody production for translational and clinical applications, antibody fragment or synthetic peptides with wellpreserved structures and functions of the binding domain to the target can be prepared as targeting ligands. Single-chain anti-EGFR antibody (ScFvEGFR) is an antibody fragment with molecular weight ranging from 25 to 28 kDa and less than 20% of the whole antibody, yet maintains the high binding affi nity and specifi city toward EGFR. [ 70 ] The ScFvEGFR conjugated IONPs have been investigated for targeted cancer imaging and therapy. [ 71, 72 ] Urokinase-type plasminogen activator receptor (uPAR) is a multidomain glycoprotein attached to the cell membrane. It has an elevated expression level in many human cancers. [ 73 ] uPAR becomes an attractive biomarker in cancer because of its critical roles in cell migration, proliferation, and survival by coordinating extracellular matrix (ECM) proteolysis and cell signaling. [ 73 ] Urokinase plasminogen activator (uPA) is the natural ligand with a high affi nity for uPAR. The amino-terminal fragment (ATF) of uPA has been successfully utilized to conjugate MNPs for uPAR targeting in breast cancer, [74] [75] [76] pancreatic cancer, [ 31, 76 ] and prostate cancer. [ 77 ] Recently, near infrared dye NIR-830 labeled insulin-like growth factor 1 (IGF-1) was used as a targeting ligand to conjugate with IONP for targeted delivery of Dox into IGF-1R positive pancreatic cancer in a orthotopic human pancreatic cancer patient tissue derived xenograft model (PDX) in nude mice. Targeted delivery of IGF-1-IONPs loaded with Dox into pancreatic tumors following systemic administration of the nanoparticles was demonstrated by T 2 -weighted MRI ( Figure 5 ). [ 22 ] Another noteworthy class of targeting ligand is aptamers, which are synthetic single-stranded oligonucleotides that are capable of binding specifi c targets with high affi nity. [ 78 ] Aptamers are synthesized through successive rounds of in vitro selection, purifi cation, and amplifi cation to yield oligonucleotides with high affi nity for a specifi c antigen. [ 79 ] More recent techniques allow in vitro selection to be carried out with whole living cells to create aptamers for specifi c cell lines. [ 80 ] By combining MNPs with the excellent recognition capability of aptamers, aptamers conjugated MNPs have shown increased binding affi nity for the target through a multivalent binding effect. [ 81 ] With a variety of aptamers being developed, the aptamer-MNP system has been tested for targeted imaging/ therapy in prostate cancer, [ 82, 83 ] and colorectal cancer. [ 84 ] Some low molecular weight small molecules can also be used as targeting moieties if they demonstrate sufficient affi nity to the targets. glycosyl-phosphatidylinositol-linked membrane protein expressed on the cell surface. The FR is typically overexpressed in cancerous tissues [ 62 ] but expressed in limited quantities on the surface of normal epithelial cells of kidney, thyroid, lung, and brain. [ 85 ] It has been reported that folic acid (FA) conjugated SPIOs demonstrated 3-to 16-fold higher uptake in FRexpressing cancer cells compared to non-conjugated SPIOs. [ 86 ] In vivo study also exhibited decreased signal intensity and enhanced contrast in tumor MRI after the injection of FA conjugated SPIOs. [ 87 ] Methotrexate (MTX) is a small molecule analogue of folic acid that can target the overexpressed folate receptors on the cancer cell surface. [ 88 ] MTX conjugated MNPs have been studied for targeted MR imaging and drug delivery of glioma. [ 30 ] Given that MTX is also a therapeutic agent, the MTX functions not only as a ligand for tumor targeting, but also as a drug when released after breaking the MTX-MNP linkage by lysosome. Integrins are transmembrane glycoproteins that are involved in the communication between cells and the extracellular matrix (ECM). [ 89 ] Among the 24 known integrins, α v β 3 is of particular interest as cancer biomarker and target for in vivo diagnostics and therapeutics, because of its key role in tumor angiogenesis as well as the high expression levels on tumor cells of various origin. [ 90 ] Arginylglycylaspartic acid, also called RGD peptide, is a tripeptide composed of L-arginine, glycine, and L-aspartic acid that can specifi cally bind with integrin α v β 3 overexpressed on cancer cells. RGD peptide has been widely used as a nanoparticle targeting ligand to facilitate tumor specifi c molecular imaging and drug delivery. [91] [92] [93] For instance, Luo et al. have reported the application of RGD conjugated ultrasmall MNPs (2.7 nm in diameter) in T 1 -weighted MRI of gliomas in mice. [ 91 ] Meanwhile, the cyclic RGD is preferred over the linear form to be conjugated onto MNPs, due to the greater affi nity to integrin α v β 3 and better stability. [ 92 ] easier to operate, several pitfalls, such as reproducibility, stability in biological media, etc., limit its wide applications. [ 94 ] On the other hand, the covalent conjugation of targeting ligands is normally adopted for MNP surface functionalizations, and a number of methods have been developed. Generally the active groups on the MNP surface for ligand conjugation include amine, carboxyl, hydroxyl, and aldehyde. By using these active groups, ligands can be conjugated either directly to the MNPs or through one of the cross-linkers summarized in Table 2 .
Surface Functionalization with Targeting Ligands
For direct conjugation of ligands, MNP surface is typically functionalized with amine (-NH 2 ) groups or carboxyl (-COOH) groups. Coupling reaction between amine and carboxyl is widely used in the conjugation of MNPs with a variety of ligands, such as aptamers, [ 82 ] proteins, [ 95 ] and small molecules, [ 96 ] for in vivo targeted MRI and drug delivery. Anhydrides are typically used in small molecule ligand conjugation by forming stable covalent bonds with amine groups. [ 96 ] When conjugating with carboxyl (-COOH) group on the surface of MNPs, amine groups from proteins, peptides, and aptamers are directly coupled by forming amide bonds with the assistance of coupling reagents, i.e., 1-ethyl-3-(3-dimethylaminopropyl)-carbodiimide (EDC) and N -hydroxysuccinimide (NHS). The MNP-conjugates are extensively investigated in vivo for tumor imaging and therapy in breast cancer, [ 74 ] prostate cancer, [75] [76] [77] 97 ] and pancreatic cancer. [ 22, 31, 71, 76 ] Additionally, aldehyde (-CHO) group can also be used for ligand conjugation on the MNP surfaces. Aldehyde group is well-known to react with primary amine to form Schiff base. [ 98, 99 ] However, the formation of Schiff base is a reversible process. In order to establish stable covalent bonds between aldehyde-bearing MNPs and protein/monoclonal antibodies, a reducing agent has to be added to convert unstable -C=N-to stable -C-N-. [ 84, 100 ] Given the limited functional groups available for direct ligand conjugation with MNPs, various linker molecules have been developed to accomplish the conjugation that cannot be achieved by direct coupling. Amine groups on the surface of MNPs can be activated with N -succinimidyl iodacetate (SIA) to be ready for reaction with thiol groups. After peptides are thiolated, they can be facilely conjugated to the MNPs. This method has been used for in vivo imaging of gliomas, [ 101 ] and pancreatic cancer. [ 102 ] Amine groups can also be activated by attaching maleimide molecules, which is highly specifi c for coupling with thiols through thiol-ene 'click' chemistry. This conjugation has been reported for in vivo glioma targeting. [ 103 ] 'Click' reaction between alkyne and azide has been reported for ligand conjugation with MNPs. The amine groups are modifi ed with synthetic linker to provide azide groups on the surface of MNPs. Peptides functionalized with alkynes are conjugated afterwards. This approach has been documented for in vivo tumor targeting. [ 104 ] Sulfosuccinimidyl 6-[3'(2-pyridyldithio)-propionamido] hexanoate (Sulfo-LC-SPDP) can be utilized in the coupling between amine groups on MNPs and amines on antibodies/peptides. Once the amine groups (both on MNPs and ligands) are activated by Sulfo-LC-SPDP, the SPDP moieties form a disulfi de bond to make the MNPs functionalized with targeting ligands. [ 69 ] When thiol groups present on the MNP surface for functionalization, the amine groups on monoclonal antibodies can be activated by sulfosuccinimidyl 4-( N -maleimidomethyl)cyclohexane-1-carboxylate (sulfo-SMCC) to introduce maleimide groups. The stable and highly specifi c coupling between thiol and maleimide makes this approach suitable for in vivo MRI of tumors. [ 105 ] Although rarely used for ligand conjugation, hydroxyl groups can react with epichlorohydrin and 2,2'-(ethylenedioxy) bisethylamie (EDBE) to introduce amine groups for conjugation. Carboxyl groups from proteins can be covalently conjugated to the MNPs, and the resulting MNP conjugate has been investigated in breast cancer imaging in vivo. [ 68 ] Adv. Funct. Mater. 2016, 26, 3818-3836 www.afm-journal.de www.MaterialsViews.com 
Strategies to Enhance Targeted Delivery of MNP Carriers

Tuning the Size and Shape of MNPs for Enhanced EPR effect
As we mentioned in Section 3.1, the EPR effect occurs in a size-dependent manner, and MNPs with sizes in the range of 10-500 nm are believed to be better for EPR effect-mediated tumor accumulation in general. [ 56 ] However, novel strategies have been reported recently to further improve the accumulation of MNPs in tumors. For example, Jain and his co-workers showed reducing the sizes of fenestrations in the walls of vessels through the anti-angiogenesis treatment, a procedure named "tumor vasculature normalization", signifi cantly decreased the interstitial fl uid pressure in tumors and demonstrated a more rapid nanoparticle (size <12 nm) extravasation. [ 57 ] On the other hand, tumor vasculature normalization increased steric and hydrodynamic hindrances, and make it more diffi cult for large nanoparticles (size >12 nm) to enter tumors. Thus, Jain's results suggested that small nanoparticles (size ≈12 nm) are ideal for tumor vasculature normalization-mediated drug delivery. Ling et al. reported on the fabrication of tumor pH-sensitive magnetic nanogrenades (termed PMNs) composed of self-assembled 3 nm IONPs and pH-responsive ligands. These PMNs can readily target tumors via surface-charge switching triggered by the acidic tumor microenvironment, and are further disassembled into highly active state in acidic subcellular compartments that "turns on" MRI contrast, fl uorescence, and photodynamic therapeutic activity, as shown in Figure 6 . [ 106 ] Although high aspect ratio MNPs showed enhanced tumor penetration, [ 119 ] developing MNPs with a high aspect ratio is still challenging. However, this can be achieved by advanced synthetic chemistry and selfassembly nanotechnology. Reproduced with permission. [ 106 ] Copyright 2014, American Chemical Society.
(BBB) and preferentially accumulate in glioblastoma multiforme (GBM) tumors after docking on the endothelia layer of the tumor blood vasculature through active targeting of tumor vasculature through conjugated RGD ligands interacting with tumor specifi c α v β 3 integrin. When coupling the MNP chain with a liposome loaded with Dox, which does not cross BBB alone, this nanochain carrier was able to deliver 4.7% of administered dose into GBM tumors, 2.7-fold more drugs than the spherical shaped MNPs, resulting in a 18.6-fold greater drug dose administered to brain tumors than standard chemotherapy. [ 107 ] 
Reducing Non-Specifi c Uptake and Prolonging Retention Time
Surface modifi cation of MNPs has a direct impact on its blood clearance, and consequently has an important infl uence on the EPR effect, ligand-to-target affi nity and drug release. When applied systemically through vascular delivery, nanoparticles are subject to immediate interactions with blood, a complex biological medium with high ionic strength and various proteins and cells. [ 108 ] Plasma proteins will non-specifi cally adsorb onto the surface of nanoparticles, also known as opsonization, forming a stable protein layer called corona. The presence of the protein corona is responsible for the fast clearance of nanoparticles by the mononuclear phagocyte system (MPS), particularly macrophages, [ 109 ] and the reticuloendothelial system (RES), such as the liver, spleen, and lung. [ 110 ] The opsonization and non-specifi c cellular uptake of nanoparticles result in the substantial reduction in targeting effi ciency and the off-target distribution of nanoparticles as well as unwanted cytotoxicity from the drug loaded on nanoparticles. Protein corona also changes the drug release profi le of nanocarriers. [ 94 ] Conventionally, dextran or PEG coating provides MNP a more hydrophilic surface that can reduce plasma protein adsorption via hydrophilicity and steric repulsion effects with the consequently prolonged circulation time in blood stream [ 111 ] long enough to reach and extravasate the leaky tumor vasculature, eventually improving the EPR effect. [ 112 ] For example, Doxil, a clinically approved, PEGylated liposomal anti-cancer drug, demonstrated a signifi cantly longer circulation half-life of 55 h than those of Myocet, Doxil's non-PEGylated counterpart (2.5 h), and the free form of Doxorubicin (0.2 h). [ 113 ] PEGylation is currently the most widely used technique for MNP coating. After the MNP coated with PEG (PEGylated), the reduction of non-specifi c cellular uptake of MNPs has been reported. [ 60 ] More recently, new coating polymers with anti-biofouling property and better performance on the reduction of non-specifi c cellular uptake and elongation of blood circulating time are developed. [ 108, 114 ] These copolymers typically contain hydrophobic moieties to anchor on the surface of MNPs. It has been reported that the hydrophobic layer provide protection to the coating materials from being replaced by biomolecules. [ 115 ] The factors determining the anti-biofouling property are still under investigation. It is believed to related to the length of PEG, the terminal functional groups on PEG, and the density of PEG distribution on the surface of nanoparticles. [ 116 ] Zwitterionic polymers are signifi cant complements to PEG on anti-biofouling coating materials. Electroneutral materials are believed to be more effective in reducing non-specifi c interactions with biological system. [ 2, 94 ] Opposite to PEG, which contains no charge, zwitterionic polymers bear both positive and negative charges on the same polymer molecule. The non-charged moiety attaches to the surface of MNPs through anchoring group, while the charged moiety will fold because of the electrostatic interactions, resulting in a protective "shield" around the MNPs. The zwitterionic polymers were initially developed to inhibit the adhesion of protein and bacteria and the formation of biofi lm. [ 117 ] Recent in vivo investigations using zwitterionic polymer coated MNPs have shown comparable anti-biofouling effect to PEG-based coating materials. [ 118 ] 
Magnetic Field Enhanced Local Delivery and Controlled Release
Since MNPs are highly responsive to an external magnetic fi eld, such very unique property makes it possible to apply magnetic fi eld directed targeting and local delivery of the MNP drug carriers. By positioning an external magnet or gradient magnetic fi eld in the diseased site, drug carrying MNPs may navigate through the physiological medium and locally accumulated in the area driven by the magnetic force from the locally applied fi eld. In this case, MNPs with high magnetic susceptibility likely possess higher local delivery effi ciency. Magnetic targeting has been demonstrated highly effective for in vitro drug delivery compared with other targeting ligand mediated delivery. [ 37 ] However, limited by the non-adjustable attractive strength and the short active reachout range, external magnetic fi eld or force based magnetic targeting is only suitable for the diseased area that are fairly superfi cial or therapy that may need a minimal invasive procedure. [ 119, 120 ] In recent years, gradient magnetic fi eld has been proved to be a useful tool to direct MNP carriers. For example, Muthana et al. utilized the magnetic fi eld gradient coil in a 7 T MRI scanner to demonstrate image-guided magnetic resonance targeting delivery of stimulated macrophages in an orthotopic prostate cancer mouse model. [ 121 ] With the magnetic targeting, the macrophage viral therapy (human monocyte-derived macrophages (MDMs) carried oncolytic virus HSV1716) exhibited greater inhibition on tumor growth and metastasis. Under an alternating magnetic fi eld (AMF), MNPs generate heat through Neel and Brownian relaxation, together with the hysteresis loss. [ 122 ] This magnetocaloric effect is utilized to heat up the diseased tissues accumulated with MNPs to reach a temperature that is high enough (>40 ºC) to enhance the reactivity and stimulate the drug release. By modifying temperature responsive materials, MNP drug carriers can control the drug release by applying external AMF. The heat generated by MNP changes the structure of the surrounding temperature sensitive materials that usually turns into loose swollen structures, leading to the release of loaded drugs. [ 13, 17 ] MNPs can also serve as sealing materials for those drug storage vehicles (e.g., mesoporous silica). [ 18 ] A controllable switching of those drug storage pools can be realized by the guidance of magnetic fi eld according to the demands.
MNPs-Based Image-Guided Delivery and Therapy
Visualizing Drug Delivery in vivo with MNPs
MNPs enable MRI-guided drug delivery, thereby offering the advantage of imaging tools to visualize drug distribution, assess targeted delivery effi ciency, and monitor/trigger drug release/ therapeutic process. Efforts have been made in optimizing MNPs based nanocarriers, together with proper imaging technologies. Currently, most MNP based image-guided drug delivery relies on, but not limited to, the MRI signal changes resulting from MNP induced MRI contrast changes, mostly by shortening T 1 and T 2 relaxation times or perturbation in susceptibility. Such MNP induced contrast enhancement enables the direct visualization of MNP drug delivery systems in tissues, including small molecule drugs, [ 22, 25, 31 ] siRNA, [ 123 ] proteins, [ 124 ] and labeled cells [ 125 ] . Hadjipannayis et al. employed IONPs to carry the epidermal growth factor receptor variant III (EGFRvIII) antibody to the U87ΔEGFRvIII mouse xenograft model of human glioblastoma multiforme (GBM) tumor. [ 124 ] Successful delivery of EGFRvIII into tumors and subsequently slow dispersion of MNP carriers at the tumor sites were evidenced by in vivo T 2 -weighted MRI on days 4 and 7 after MNPs were administered. This treatment resulted in a signifi cant increase in animal survival. However, the negative T 2 -or T 2 *-weighted MRI are known to have drawbacks in differentiating the areas of interest from the artifacts and poor contrast when background tissues have low signal, such as the tumors located in the peritoneal cavity. Recently, an ultrashort TE (UTE) MRI based on T 1 or a positive contrast enhancement from MNPs was introduced to visualize the MNP labeled cells and MNPs administered to animals. [ 126 ] T 1 -weighted UTE MRI was demonstrated to enhance the detecting sensitivity of residual pancreatic tumors in the peritoneal cavity of mice bearing orthotopic human pancreatic tumor after the treatment with IONPs conjugated with uPAR targeting ATF ligand and chemotherapy agent gemcitabine (ATF-IONP-Gem) for targeted delivery of Gem to pancreatic cancerous and stromal cells ( Reproduced with permission. [ 31 ] Copyright 2013, American Chemical Society. B) Combination nanoablation and nanoembolization versus nanoembolization alone in VX2 rabbit liver cancer model on 7T MRI. Representative axial T 2 *W GRE images (TE: 11.9 ms) with corresponding R 2 * parametric maps from the same animal. Combination therapy resulted in signifi cant signal change within tumor core and periphery, as depicted in red. Right panel is biodistribution of DOX-SPIOs in tumor and liver tissue following combination therapy (nanoembolization followed by nanoablation) in VX2 rabbit model. (p < 0.05). Reproduced with permission. [ 128 ] Copyright 2013, American Chemical Society.
wileyonlinelibrary.com © 2016 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim UTE imaging. [ 31 ] as well as signal drops in T 2 -weighted MRI, demonstrating higher tumor accumulation of ATF-IONP-Gem than non-targeted IONP-Gem and thus provided a more effi cient tumor inhibition effect. Although largely under development, the strategies for quantifying drug delivery using MNPs have been explored based on the relationships between MRI signal changes and MNP concentration, [ 127 ] a potential critical capability for MNP based image-guided drug delivery system. Mouli et al. directly compared the effi ciency of different drug delivery strategies with IONPs loaded with Dox by quantitatively measuring the ΔR 2 * of the tumors (Figure 7 B) . [ 128 ] Combination therapy of nanoablation and nanoembolization was found to be the most effi cient way to deliver Dox loaded MNPs into the tumor, with the greatest T 2 * signal drop in both the tumor core and periphery areas. Ex vivo ICP-MS quantifi cation of the tumors further confi rmed the greatest uptake of Dox loaded MNPs in the combination therapy.
Besides visualizing and quantifying the delivery location and amount, MNPs can also provide longitudinal information about the drug status (i.e., released or not). Generally, MRI contrast agents (normally Gd chelate agents) are incorporated with drugs in liposomes or polymer based micelles. Non-invasive MRI can monitor the delivery and quantify the released contents via the contrast changes. Rizzitelli et al. detected the release of Dox from nanocarriers that incorporated Dox with MRI contrast agent Gadoteridol in liposome. [ 129 ] A significant increase in T 1 contrast to noise ratio (CNR) in tumors was observed after pLINFU stimulation, indicating the successful release of Gadoteridol and Dox from the liposome. The drug concentration can be monitored by this CNR (T 1 ), which showed a spike after stimulation, and decreased within 6 h, following slow increase from day 1 to day 3 and 4 and then diminished on day 7. Li et al. also reported T 1 MR signal enhancement in the periphery area of the tumor at 60 min after i.v. injection of their nanoplex, composed of PEI/siRNAchk/PLL-DOTA-Gd/Cy5.5/bCD-111, and in the central region of the tumor after 24 h and 48 h. [ 130 ] siRNA-mediated downregulation of Chk-α and the conversion of 5-FC to 5-FU by the prodrug enzyme bacterial cytosine deaminase (bCD) were monitored noninvasively with 1 H MR spectroscopic imaging and 19 F MR spectroscopy ( Figure 8 ). The spatio-temporal guidance of the drug release provided by MRI allowed for evaluating the therapeutic effi ciency individually to assure the ontime adjustment of the treatment plan.
Other imaging approaches, such as ultrasound, [ 108 ] photoacoustic, [ 99, 120, [131] [132] [133] CT, [ 134 ] PET/SPECT, [ 135 ] and optical [ 22, 25, [133] [134] [135] imaging, have been involved in the MNPsbased image-guided drug delivery, in order to provide more accurate image guidance. Multimodal imaging approaches can be readily achieved by combining MNPs with other imaging moieties. Recently we developed an oral drug delivery system based on milk protein coated IONP, in which model drug ICG was incorporated into the inner polymer layer. [ 25 ] The successful delivery of MNPs with protein coating protection to the small intestine was observed by both MRI and NIR imaging, while the bare MNPs without protein coating was observed being trapped in the stomach. Another example by Zhou et al. demonstrated systemic delivery of IGF1 conjugated IONP carrying Dox with MRI assessment of the drug delivery in a human pancreatic cancer PDX model, showing higher delivery effi ciency and therapeutic effect of targeted IGF1-IONP-Dox. [ F MRS demonstrated effi cient conversion of prodrug 5-FC to 5-FU and its metabolites F-Nucl by nanoplex localized in the tumor. 5-FC was injected at 24 h after nanoplex injection. D) Representative in vivo tCho maps and color-coded tCho intensity maps overlaid on corresponding T 1 -weighted images of a tumor before and at 24 and 48 h after nanoplex injection, displaying spatial siRNA-mediated downregulation of Chk-α. Reproduced with permission. [ 130 ] Copyright 2010, American Chemical Society.
Tang et al. quantitatively tracked labeled mesenchymal stem cells (MSC) transplanted intracerebrally or intravenously into stroke rats by MRI/SPECT/fl uorescent trimodal imaging. [ 135 ] The signal lasted up to 14 days, allowing for the determination of MSCs distribution after both groups showed improved neurobehavior. IC-injected MSCs was found to migrate to the lesion site along the corpus callosum, while IV-injected MSCs were mainly trapped in lung.
Image-Guided Combination Therapy with MNPs
In addition to visualizing drug delivery with MRI or multimodal imaging, MNPs advance in combination therapy with image-guided deposition of exogenous energy. Either MNPs or the loaded nanoresponsors are stimulated to generate high temperature or trigger drug release via light, [ 131 ] magnetic, [ 107 ] acoustic [ 129 ] or radioactive energy. [ 46 ] Among them, hyperthermia has been considered as an additive therapy method of chemotherapy and radiotherapy, where high temperature (>40 ºC) that accelerates cell apoptosis is achieved by applying AMF at the diseased sites that accumulated with MNPs. [ 122 ] For example, improved in vivo therapeutic effi cacy was observed for the combination of hyperthermia and chemotherapy of multiple myeloma by using smart MNP carriers loaded with Dox ( Figure 9 ). [ 28 ] Although magnetic hyperthermia produced by radiofrequency/AMF emerged as the earliest approach, the discomfort at higher magnetic fi eld strengths and irregular intratumoural heat distribution limit its application. [ 136 ] The ongoing research mainly focuses on developing more effi cient MNPs to escape from RES uptake and effectively target to the lesions. The combination of magnetic hyperthermia and radiotherapy has been proved to be clinically effective in brain cancer and prostate cancer patients undergoing phase II trials in humans. [ 137 ] Other researches have tried to enhance the therapeutic effect by combining MNPs with radiosensitive materials/drugs (e.g., gold nanoparticles and Mitomycin C). [ 46, 138 ] Recently, photothermal therapy under MRI guidance has attracted great attention because of its convenience and efficacy. Photo-absorbing nanomaterials, such as upconversion materials, [ 139 ] metal sulfi de nanoparticles (e.g., Co 9 Se 8 [ 131 ] and FeS [ 140 ] ), carboneous materials (e.g., graphene oxide, [ 141 ] Fe 2 C 5 , [ 99 ] porphyrin [ 132 ] and polypyrrole [ 142 ] ), NIR dyes (e.g., IR825 [ 133 ] and Pheophorbide A [ 143 ] ), and gold nanomaterials [ 144 ] are integrated with MNPs to generate heat at the desired location indicated by MRI anatomic information, and being monitored with the temperature by MR thermometry (e.g., proton resonance frequency shift method).
High intensity focused ultrasound (HIFU) is considered to be another promising hyperthermia methodology that elevates MNPs-based drug delivery. This approach delivers highfrequency focused mechanical sound waves through an ultrasound transducer to generate heat locally in the tissue. [ 145 ] During the process, the temperature-sensitive liposomes loaded with drug and MRI contrast agents are disrupted to provide MR contrast in real time. [ 13 ] The changes of local tissue pressure and possible tissue displacement induced by acoustic energy may facilitate the permeation and diffusion of the released drugs into deep tissue and target cells. [ 146 ] 
Conclusion and Perspectives
With increased emphasis on precision medicine, the targeted and image-guided drug delivery is expected to play a major role in the individualized treatment of human cancers and other diseases. Highly heterogeneous human cancer cells and tumor microenvironment requires novel drug delivery approaches and non-invasive imaging methods to assess drug delivery effi ciency and tumor responses to the therapy in individual patients. Although genomic profi ling of tumor biopsy tissues, a common approach for precision medicine, may characterize the disease based on intrinsic properties of tumor cells that may be associated with drug sensitivity, it is diffi cult to provide the information on the effi ciency of drug delivery to tumors in individual patients at different stages of tumor development and under a particular treatment or different treatments since tumor vasculatures and tumor microenvironment affect intratumoral drug delivery and distribution. MNP-based drug carriers have great potentials to deliver precision oncology with assistance of imaging capabilities, such as MRI, therefore, offering non-invasive and longitudinal imaging assessment to evaluate biomarker targeted nanoparticle-drug delivery and even intratumoral distribution of the drug carrier, because determining the option for biomarker targeted treatment and the need of targeted therapy delivery as well as treatment monitoring may be a part of the very early step in the treatment planning in the practice of precision medicine. Additionally, multifunctional MNPs enable delivery of combination drugs, stimulation controlled drug release, sensitizing drug action that can lead to improved therapeutic sensitivity. It is expected that engineered MNPs continue to be an attractive platform for the future development of theranostic applications that implement the targeted and image-guided delivery. The future development of MNPs for drug delivery applications are dependent on the more and better understanding of the nanoparticle delivery mechanisms in various diseases. The systematical investigation and new knowledge on the interface between the engineered nanomaterials and biological environments at various physical conditions, anatomic locations and different tissue environments are necessary when designing and implementing MNPs based drug delivery systems to a specifi c biological system or disease. Developing innovative ideas and approaches to explore potential functions and capabilities of MNPs in drug delivery and imaging applications should have clear vision on the healthcare problems and clinical applications. While a wide range of engineered MNPs are developed for drug delivery in laboratory research and preclinical studies, the clinical translations of these developed new nanomaterials are challenging. There are urgent needs in addressing several issues in translational research. Optimized and scale-up ready MNP fabrications are essential to developing pre-clinical and clinical applications. Standardization of MNP characterizations with quantitative assessments of their effi cacies and capabilities is of critical importance and needs to be established. To improve the clearance and safety and signifi cantly decrease the off-target effects of theranostic MNPs in normal organs, such as liver and spleen, current research efforts have focused on the development of a new generation of ultrafi ne MNPs (<3 nm) with high biodegradability for fast clearance [ 147 ] and anti-fouling polymer www.afm-journal.de www.MaterialsViews.com Figure 9 . Combination chemotherapy and hyperthermia with MNP carriers. A) Illustration of MNP carriers that produce heat in response to AMF and sequentially release Dox. B) Illustration of cancer treatment with the combination of magnetic hyperthermia and chemotherapy using the smart NPs. Change of C) tumor volume, D) survival rate, and E) body weight: non-treated mice (black), mice treated with chemotherapy (yellow), mice exposed to AMF (green), mice injected with Fe 3 O 4 /Dox/PPy-PEG-FA NPs intratumorally (purple), mice treated with magnetic hyperthermia (blue), and mice treated with the combination of magnetic hyperthermia and chemotherapy (red). F) Photographs of non-treated mice, mice treated with chemotherapy, mice exposed to AMF, mice injected with Fe3O4/Dox/PPy-PEG-FA NPs intratumorally, mice treated with magnetic hyperthermia, and mice treated with the combination of magnetic hyperthermia and chemotherapy 45 days after treatment. Reproduced with permission. [ 28 ] Copyright 2015, Ivyspring International Publisher.
www.afm-journal.de www.MaterialsViews.com coating for reducing nonspecifi c uptake by macrophages and RES organs. As nanomedicine continues to grow and makes impact on future medicine, there is a promising future for a broad range of clinical applications of MNP-based imageguided targeted delivery.
